Primary Rituximab and Maintenance

PHASE3CompletedINTERVENTIONAL
Enrollment

1,217

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

May 31, 2007

Study Completion Date

December 31, 2016

Conditions
Follicular Lymphoma
Interventions
DRUG

Rituximab

rituximab 375 mg/m2 every 8 weeks for 24 months (12 injections) or control with no treatment

Trial Locations (24)

31059

Hématologie CHU Purpan, Toulouse

33300

Polyclinique Bordeaux Nord, Bordeaux

51092

Centre Hospitalier Robert Debré, Reims

59000

Hématologie CHU de Lille, Lille

69008

Centre Léon Bérard, Lyon

69495

Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite

75005

Institut Curie, Paris

75010

Hôpital Saint Louis, Paris

75743

Hématologie Adultes - Hôpital Necker, Paris

76038

Centre Henri Becquerel, Rouen

94010

Hôpital Henri Mondor, Créteil

CP C1114AAN

Fundaleu Hospital, Buenos Aires

Unknown

Australian Leukemia and Lymphoma Group, Melbourne

Université de Gent, Ghent

Groupe d'Etude des Lymphomes de l'adulte, Mont-Godinne

Hospital Samaritano, São Paulo

Fundación Santafé de Bogotá, Bogotá

Amtssygehuset i Herlev, Herlev

Institut Gustave Roussy, Villejuif

HOVON, Utrecht

Australia New Zealand Leukemia Lymphoma Group, Auckland

Instituo Nacional de Enfermedades Neoplasicas, Lima

Hospital Clinic Barcelona, Barcelona

King Chulalongkorn Memorial Hospital, Bangkok

All Listed Sponsors
collaborator

HOVON - Dutch Haemato-Oncology Association

OTHER

collaborator

German Low Grade Lymphoma Study Group

OTHER

collaborator

Australasian Leukaemia and Lymphoma Group

OTHER

collaborator

Institute of Cancer Research, United Kingdom

OTHER

lead

Lymphoma Study Association

OTHER

NCT00140582 - Primary Rituximab and Maintenance | Biotech Hunter | Biotech Hunter